Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial (vol 116, pg 191, 2016)

S Barco; M Lankeit; H Binder; S Schellong; Michael Christ; J Beyer-Westendorf; D Duerschmied; R Bauersachs; K Empen; M Held; M Schwaiblmair; C Fonseca; D Jimenez; C Becattini; K Quitzau; C Espinola-Klein; P Wild; S Konstantinides

doi:10.1160/TH16100001

Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial (vol 116, pg 191, 2016)

S Barco, M Lankeit, H Binder, S Schellong, Michael Christ (Co-author), J Beyer-Westendorf, D Duerschmied, R Bauersachs, K Empen, M Held, M Schwaiblmair, C Fonseca, D Jimenez, C Becattini, K Quitzau, C Espinola-Klein, P Wild, S Konstantinides

Department of Emergency and Critical Care Medicine (until 31st of January, 2017)

Research output: Contribution to journal › Correction › peer-review

Original language	English
Pages (from-to)	775-775
Journal	THROMBOSIS AND HAEMOSTASIS
Volume	116
Issue number	4
DOIs	https://doi.org/10.1160/TH16100001
Publication status	Published - 2016

Access to Document

10.1160/TH16100001

Cite this

Barco, S., Lankeit, M., Binder, H., Schellong, S., Christ, M., Beyer-Westendorf, J., Duerschmied, D., Bauersachs, R., Empen, K., Held, M., Schwaiblmair, M., Fonseca, C., Jimenez, D., Becattini, C., Quitzau, K., Espinola-Klein, C., Wild, P., & Konstantinides, S. (2016). Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial (vol 116, pg 191, 2016). THROMBOSIS AND HAEMOSTASIS , 116(4), 775-775. https://doi.org/10.1160/TH16100001

Barco, S ; Lankeit, M ; Binder, H et al. / Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial (vol 116, pg 191, 2016). In: THROMBOSIS AND HAEMOSTASIS 2016 ; Vol. 116, No. 4. pp. 775-775.

@article{d058237e68c6426eb175cd6e3b8fc9b2,

title = "Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial (vol 116, pg 191, 2016)",

author = "S Barco and M Lankeit and H Binder and S Schellong and Michael Christ and J Beyer-Westendorf and D Duerschmied and R Bauersachs and K Empen and M Held and M Schwaiblmair and C Fonseca and D Jimenez and C Becattini and K Quitzau and C Espinola-Klein and P Wild and S Konstantinides",

year = "2016",

doi = "10.1160/TH16100001",

language = "English",

volume = "116",

pages = "775--775",

journal = "THROMBOSIS AND HAEMOSTASIS ",

issn = "0340-6245",

number = "4",

}

Barco, S, Lankeit, M, Binder, H, Schellong, S, Christ, M, Beyer-Westendorf, J, Duerschmied, D, Bauersachs, R, Empen, K, Held, M, Schwaiblmair, M, Fonseca, C, Jimenez, D, Becattini, C, Quitzau, K, Espinola-Klein, C, Wild, P & Konstantinides, S 2016, 'Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial (vol 116, pg 191, 2016)', THROMBOSIS AND HAEMOSTASIS , vol. 116, no. 4, pp. 775-775. https://doi.org/10.1160/TH16100001

Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial (vol 116, pg 191, 2016). / Barco, S; Lankeit, M; Binder, H et al.
In: THROMBOSIS AND HAEMOSTASIS , Vol. 116, No. 4, 2016, p. 775-775.

Research output: Contribution to journal › Correction › peer-review

TY - JOUR

T1 - Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial (vol 116, pg 191, 2016)

AU - Barco, S

AU - Lankeit, M

AU - Binder, H

AU - Schellong, S

AU - Christ, Michael

AU - Beyer-Westendorf, J

AU - Duerschmied, D

AU - Bauersachs, R

AU - Empen, K

AU - Held, M

AU - Schwaiblmair, M

AU - Fonseca, C

AU - Jimenez, D

AU - Becattini, C

AU - Quitzau, K

AU - Espinola-Klein, C

AU - Wild, P

AU - Konstantinides, S

PY - 2016

Y1 - 2016

U2 - 10.1160/TH16100001

DO - 10.1160/TH16100001

M3 - Correction

SN - 0340-6245

VL - 116

SP - 775

EP - 775

JO - THROMBOSIS AND HAEMOSTASIS

JF - THROMBOSIS AND HAEMOSTASIS

IS - 4

ER -

Barco S, Lankeit M, Binder H, Schellong S, Christ M, Beyer-Westendorf J et al. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial (vol 116, pg 191, 2016). THROMBOSIS AND HAEMOSTASIS . 2016;116(4):775-775. doi: 10.1160/TH16100001